A retrospective study examined 12 patients with NSCLC who were administered pembrolizumab rechallenge after pausing initial nivolumab treatment; the authors found that all patients who showed responses (PR and SD) had high PD-L1 expression (tumor proportion score ≥80%) 56. Here, CD274 is linked to neoplasm.